Inhibikase Therapeutics, Inc.
IKT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IKT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IKT
Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage biopharmaceutical company developing IKT-001 for pulmonary arterial hypertension (PAH), currently in a global Phase 3 study (IMPROVE-PAH) with no approved products or revenue.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Market Cap
$336.3M
Cash Runway
37.0 moLead Asset
ikt-001 (Phase 3)
Next Catalyst
Phase3_Topline · Dec 1, 2029Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials · 2 catalysts for Inhibikase Therapeutics, Inc..
Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage biopharmaceutical company developing IKT-001 for pulmonary arterial hypertension (PAH), currently in a global Phase 3 study (IMPROVE-PAH) with no approved products or revenue.
- Cash & equivalents of $31.2M as of 2026-06-30 [sec].
- Net loss of $19.6M for the six months ended 2026-06-30 [sec].
- Lead candidate IKT-001 is in a global Phase 3 trial (IMPROVE-PAH) for pulmonary arterial hypertension [sec_mda · as of 2026-08-11].
- No revenue from product sales; company expects to continue incurring significant losses [sec_mda · as of 2026-08-11].
- Cash runway estimated to support operations through topline data readout in Part B of the Phase 3 study, assuming full exercise of outstanding warrants [sec_mda · as of 2026-08-11].
What works
- Cash position of $31.2M as of 2026-06-30 provides near-term funding for ongoing Phase 3 trial [sec].
- Management estimates existing cash plus ATM proceeds will support operations through topline data readout in Part B of the Phase 3 IMPROVE-PAH study [sec_mda · as of 2026-08-11].
- Company has a single, focused lead candidate (IKT-001) in a Phase 3 trial, reducing pipeline complexity [sec_mda · as of 2026-08-11].
What to weigh
- No approved products or revenue; company has never generated product sales and expects continued losses [sec_mda · as of 2026-08-11].
- Net loss of $19.6M for the six months ended 2026-06-30 indicates significant cash burn [sec].
- Cash runway depends on assumptions that may prove wrong, and capital may be depleted sooner than planned [sec_mda · as of 2026-08-11].
- Drug development is inherently risky; the company faces uncertainty in completing trials, obtaining regulatory approval, and commercializing IKT-001 [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
No significant revenue from product sales expected until regulatory approval
“We do not expect to generate any significant revenue from product sales unless and until we obtain regulatory approval of and successfully commercialize any of our product candidates”
SEC MD&A · August 11, 2026
Cash runway through topline data readout in Part B of Phase 3 study
“will support operations through topline data readout in Part B of our ongoing global Phase 3 IMPROVE-PAH clinical study”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2029-12-01 · Phase3_Topline — Phase 3 Topline: An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and — Topline efficacy and safety data from Part B of the Phase 3 IMPROVE-PAH study are expected.
- 2030-12-30 · Phase3_Topline — Phase 3 Topline: Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonar — Topline safety and tolerability data from the open-label long-term extension study are expected.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Company has no commercial products and expects no significant revenue until regulatory approval [sec_mda · as of 2026-08-11].
- Significant net loss and cash burn — Net loss of $19.6M in six months ended 2026-06-30; cash may be depleted sooner than planned [sec].
- Clinical and regulatory uncertainty — Drug development involves numerous risks: trial enrollment, safety, efficacy, FDA approval [sec_mda · as of 2026-08-11].
- Dependence on warrant exercise — Cash runway estimate assumes full and timely exercise of outstanding warrants, which may not occur [sec_mda · as of 2026-08-11].
What to watch
- Topline data readout from Part B of the Phase 3 IMPROVE-PAH study (expected catalyst date 2029-12-01) [catalyst].
- Open-label long-term extension study results for IKT-001 (expected catalyst date 2030-12-30) [catalyst].
- Cash burn rate and any additional capital raises or warrant exercises [sec_mda · as of 2026-08-11].
- Regulatory interactions and potential NDA filing for IKT-001 [sec_mda · as of 2026-08-11].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Inhibikase Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Inhibikase Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
37.0 months
D/E 0.07 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~1189d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
99
Total value held
$130.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 8,901,330 | $15.0M |
| adar1 capital management, llc | 6,606,572 | $11.1M |
| kalehua capital management llc | 6,494,498 | $10.9M |
| blackrock, inc. | 6,303,433 | $10.6M |
| blackstone inc. | 5,938,276 | $10.0M |
| commodore capital lp | 5,397,488 | $9.1M |
| perceptive advisors llc | 4,630,000 | $7.8M |
| saturn v capital management lp | 3,863,445 | $6.5M |
| spruce street capital lp | 3,581,603 | $6.0M |
| squadron capital management llc | 3,500,000 | $5.9M |
Showing top 10 of 99 institutional holders of Inhibikase Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 21.9%
- Days to cover
- 18.3
- Shares short
- 17,979,022
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IKT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Inhibikase Therapeutics, Inc.?
Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage biopharmaceutical company developing IKT-001 for pulmonary arterial hypertension (PAH), currently in a global Phase 3 study (IMPROVE-PAH) with no approved products or revenue.
What is Inhibikase Therapeutics, Inc.'s lead drug candidate?
Inhibikase Therapeutics, Inc.'s most advanced tracked candidate is ikt-001 (Phase 3) for Pulmonary Arterial Hypertension; Pulmonary Arterial Hypertension (PAH).
What is Inhibikase Therapeutics, Inc.'s next catalyst?
Inhibikase Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and" — expected December 1, 2029.
Who is the CEO of Inhibikase Therapeutics, Inc.?
Mr. Mark T. Iwicki is the chief executive officer of Inhibikase Therapeutics, Inc. (IKT).
Where is Inhibikase Therapeutics, Inc. headquartered?
Inhibikase Therapeutics, Inc. (IKT) is headquartered in Wilmington, DE, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.